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The problem of access to medicines became acute with the entry of the 
Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement in 
1995 and caught a number of developing countries around the world, 
unawares. Brenda P Mey’s book on access to drugs issues is a study of this 
particular problem faced in two developing countries, namely India and 
Kenya in the aftermath of the implementation of the TRIPS compliant patent 
legislation. The two developing countries taken up for study are 
geographically located in two different continents, namely Asia and Africa 
with differing backgrounds and strikingly similar problems. Dr Mey’s book is 
a brainchild of her PhD thesis of the same title, and a library reference work in 
every sense. It showcases her talents as a researcher and analyst on the subject 
matter of lack of access to medicines (in this case India and Kenya) as a direct 
result from the implementation of TRIPS Agreement, which grants an 
extended patent protection to pharmaceutical and chemical products besides 
others.  
Most developing countries and least developed countries were not fully 
aware of the consequences of an extended pharmaceutical patent protection 
sought to be introduced through the World Trade Organization’s (WTO) 
multilateral trading system, and were hence not fully prepared when the 
TRIPS Agreement was implemented. India and Kenya, who produce 
affordable off-patent generic medicines which in turn are widely used in 
frontline treatment of diseases like HIV/AIDS, malaria, etc., in other 
developing countries and least developed countries around the world. Both 
India and Kenya, as members of the WTO were required to introduce TRIPS 
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compliant intellectual property legislation into their domestic laws, which was 
to impact their pharmaceutical industry, particularly their capacity to produce 
and export generic medicines. Notwithstanding the impact on domestic 
manufacturing of generic medicines, the TRIPS Agreement had also seriously 
affected the access to affordable medicines for millions of people around the 
world due to a multi-fold increase of patented pharmaceutical products. The 
overall theme of the book focuses on the extent to which the IP rights regime 
(including flexibilities) introduced under the TRIPS Agreement has been used 
as a tool for enabling access to affordable medicines in India and Kenya, and 
the effect of the TRIPS regime on their domestic pharmaceutical industry.   
As the book is based on the author’s PhD thesis, the groundwork is 
detailed and the questions raised to achieve the goals set out are clear and 
specific. The core objective of the book is to find answers to the question 
posed in the title through the examination of provisions relating to the 
protection of pharmaceutical patents contained in the TRIPS Agreement, and 
in the domestic patent law legislations implemented in India and Kenya 
following the entry of the TRIPS Agreement. The key questions raised on the 
above theme are, i) what flexibilities are built into the TRIPS to assist the 
developing  country member states (especially to suit Kenya and India), to 
enable them to pursue pro-public health policies geared at facilitating access 
to medicines; ii) what are the limits that prevent the application of these 
flexibilities at national levels; iii) how the obligation to promote and protect 
the right to health may limit the exploitation of the flexibilities contained in 
the TRIPS Agreement; iv) how have the two countries, Kenya and India, 
exploited the flexibilities at national levels to promote cost-effectiveness in 
their health sectors, while still acting within the overall confines of the 
TRIPS; and lastly v) what are the problems encountered by Kenya and India 
in the effective implementation of the flexibilities. The use of a range of 
research methodologies including exploratory, descriptive, qualitative and 
quantitative methodologies, and interpretation and analysis of court cases, 
benefits the work. In particular, Kenya’s and India’s experience with the 
actual implementation of the TRIPS has been clearly brought out. The use of 
different methodologies has been attributed to the fact that the study is 
interdisciplinary and not limited to intellectual property rights protection.  
As a precursor to the case studies, Dr Mey has devoted a chapter of the 
book to the study of the philosophical foundations/justification for grant of 
extended protection for pharmaceutical patents under the TRIPS Agreement. 
This chapter with the analysis of property rights theories, tracing the origins 
from the utilitarianism to the incentive based economic justifications. Dr Mey 
covers the theories propounded by Locke, Kant and Hegel, Hume and 
Bentham to the more recent works of Hettinger Lemley from the twentieth 
century. This part of the book is probably one of the most important areas of 
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the study, as it also seeks to balance the justification for patent protection with 
the right to life contained in various international conventions, including 
Universal Declaration of Human Rights (UDHR), International Convention 
on Economic Social and Cultural Rights (ICESCR), and in other regional 
human rights instruments like the African Charter on Human and Peoples 
Rights (ACHPR).       
In her quest to seek answers to the above lead questions, Dr Mey carefully 
presents the historical background of both countries taken up for study. Kenya 
and India both former British colonies inherited from their common colonial 
ruler parliamentary democracy, civic administration, and the common-law 
legal systems (including IP rights legislations and practices). Kenya and 
India’s IP laws mirrored Britain’s patent system dating back to 1856, and 
were replaced in later years in the post-colonial era. One other reason for the 
comparative study of patent laws in Kenya and India is attributable to the fact 
that both Kenya (in sub-Saharan Africa) and India (Asia) possess a healthy 
pharmaceutical industry (developed in their post-colonial era), yet the two 
countries are worlds apart. The Indian pharmaceutical sector is, in comparison 
to Kenya’s, much more advanced and remains a major supplier of 
pharmaceuticals products to both Kenya, and other developing countries. 
Indian pharmaceutical sector, although produces bulk drugs for most disease 
segments, is still mainly dominated by generics medicines developed on the 
back of a process patent system introduced in the pre-TRIPS era. This 
legislation was introduced in India in 1971, on the back of recommendations 
from the Justice Iyyangar Committee, which recommended a clear departure 
from the product patent model introduced under British rule. With the above 
laws from 1971, India was able to address the public health concerns 
domestically and also at the same time accord the foreign patent holders 
operating in India some form of protection for their inventions.  
All this was to change with the entry of the TRIPS Agreement in 1995, 
which introduced a product patent system and a 20-year period of patent 
protection for pharmaceutical products and others. India, till such time it 
introduced the TRIPS compliant patent laws, had for years been an important 
supplier of affordable generic pharmaceutical products to many developing 
countries. To put things in perspective, African countries account for 15% of 
India’s US $8 billion pharmaceutical exports. Kenya, the third-largest African 
market for generic drugs from India, is estimated to have imported drugs 
worth more than US $70 million in 2008. The introduction of the TRIPS 
Agreement had not only seen a rise in the prices of patented pharmaceutical 
products in developing countries, who don’t have a proper health care system, 
but also has seen the drying up of affordable generic pharmaceutical products 
from India. One of the populations seriously affected from the problem is 
those affected by HIV/AIDS and living in developing countries and least 
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developed countries, and in particular in sub-Saharan Africa, as they are 
unable to access frontline antiretroviral (ARV) drugs for their treatment.   
Coming to the social economic conditions of the Kenya and India, the Dr 
Mey points out that although Kenya is classified alongside India as a 
developing country, its industrial development and scientific capacity is not as 
advanced as India’s. She most importantly observes that intellectual property 
rights can be said to be better established in Kenya than in India through 
patent laws that are fully TRIPS-compliant. She is also quick to point out that 
problems of corruption, weak institutional and regulatory frameworks for 
implementing and enforcing IP rights have “continually restricted the ability 
of both countries to effectively protect and enforce their IP rights in a manner 
that allows them to progressively participate in international trade 
negotiations and international standard-setting processes.” The introduction of 
intellectual property rights protection in the WTO negotiation process and 
thereafter in the multilateral trading system is dealt with clearly, and so is the 
opposition from the developing country member states of the WTO. It is very 
obvious that the work is based on a PhD thesis as demonstrated by the 
structure, the research questions raised and the methodologies and the style 
employed. This does not in any way diminish the intensity of the work in 
addressing the key issue of access to medicines in India and Kenya, with the 
entry of the TRIPS Agreement.    
While intellectual property laws are said to encourage innovation and 
remains an interesting area of study in the twenty first century, the 
enforcement of the intellectual property rights relating to pharmaceutical 
products at the WTO, through the instrument of TRIPS Agreement appears to 
be strained, and coming at a heavy cost, i.e., human cost. There had been a 
few titles on the subject of access to medicines, and the plight of the patience 
in developing countries who suffer needlessly due to the extended protection 
afforded to pharmaceutical patents under the TRIPS Agreement, but the one 
under review is different and presents a balanced study of two developing 
countries who have a developed pharmaceutical sector in the post-colonial 
era, but have struggled in the implementation of the TRIPS Agreement. For 
the serious researcher, the book by Dr Mey presents a stark picture of the 
realities of access to medicines in the developing countries of India and 
Kenya, and how the reality in the ground had changed since the 
implementation of the TRIPS Agreement into their statute books. Overall, Dr 
Mey’s book is well researched, presenting a sensitive picture and offering an 
insight into the legal, political and economic realities of the problems faced by 
the two countries in their efforts to find a balance in the implementation of the 
TRIPS Agreement.     
 
